In vitro safety pharmacology profiling: what else beyond hERG?

In vitro safety pharmacology profiling: what else beyond hERG?

Item
http://www.wikidata.org/entity/Q37855844
In silico mechanistic profiling to probe small molecule binding to sulfotransferasesConcordance and predictive value of two adverse drug event data sets.A bioluminescence method for direct measurement of phosphodiesterase activity.Challenges in antimalarial drug discovery.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Computational Biology and Chemistry in MTi: Emphasis on the Prediction of Some ADMET Properties.Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.Maximizing the outcome of early ADMET models: strategies to win the drug-hunting battles?Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.
P2860

In vitro safety pharmacology profiling: what else beyond hERG?

Item
http://www.wikidata.org/entity/Q37855844
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro safety pharmacology profiling: what else beyond hERG?
@en
In vitro safety pharmacology profiling: what else beyond hERG?
@nl
type
label
In vitro safety pharmacology profiling: what else beyond hERG?
@en
In vitro safety pharmacology profiling: what else beyond hERG?
@nl
prefLabel
In vitro safety pharmacology profiling: what else beyond hERG?
@en
In vitro safety pharmacology profiling: what else beyond hERG?
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
In vitro safety pharmacology profiling: what else beyond hERG?
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921